Cureboard
Search the catalogue
Loading…
Rapamycin mtor | Cureboard
Findings
Datasets
About
Rapamycin mtor
1 entry on this topic
1
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Researchers fed rapamycin, an mTOR pathway inhibitor, to genetically heterogeneous mice starting at 600 days of age and measured survival across three independent test sites. Rapamycin extended median and maximal lifespan in both sexes, with an estimated 14% increase in age at 90% mortality for females and 9% for males. A separate study starting treatment at 270 days also showed improved survival based on an interim analysis near median survival.
Animal study
Paper, Nature, 1 Jul 2009